Following MAH pilot, WuXi STA to support Antengene oncology research

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Jirsk)
(Image: Getty/Jirsk)

Related tags: Oncology, marketing authorization, Marketing, Packaging, API

STA Pharmaceutical has entered an agreement with China-based Antengene to provide R&D for its oncology pipeline using its ‘end-to-end’ CMC platform.

The agreement between the Chinese contract development and manufacturing organization (CDMO) STA Pharmaceutical, a WuXi AppTec company, and Antengene, follows China’s 2016 Marketing Authorization Holder (MAH)​ pilot program.

The MAH program​ allows drug license holders to use a third party manufacturer instead of building GMP manufacturing capabilities in-house, as was previously required.

Jinling Chen, VP of pharmaceutical development services at STA Pharmaceutical, a WuXi AppTec company, told us the company was the first CDMO to support a drug launch through the MAH program. 

As an integrated CDMO, Chen explained that having both its drug substance and drug product research and development (R&D) services in the same facility enables “frictionless”​ communication as the molecule moves down the pipeline.

“Making the drug substance and drug product in one company in close proximity, working together with a shared quality program saves critical time in the race to reach patients,” ​said Chen.

"Having the supply chain within one company, with each group is geographic proximity, saves time in shipping, release testing, and method transfers," ​she added.

Related news

Show more

Related products

show more

Innovations in OSD

Innovations in OSD


This DFE series of educational webinars looks at innovations in Oral Solid Dose Forms with the emergence of advanced technologies such as Continuous Manufacturing...

Register for free

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us


View more